ArticleNature medicine2022
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed, 4 pooled it
16.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
115 citing papers in PubMed, 4 syntheses or guidelines pooled it, 172 citations in OpenAlex.
- The Predictive Role of ctDNA and CTCs in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- The prognostic role of circulating DNA markers in patients with lung malignancies: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Clinical Validity and Utility of Circulating Tumor DNA (ctDNA) Testing in Advanced Non-small Cell Lung Cancer (aNSCLC): A Systematic Literature Review and Meta-analysis.Molecular diagnosis & therapy · 2024 · on this mapPooled it
- Prognostic value of circulating tumor DNA in operable non-small cell lung cancer: a systematic review and reconstructed individual patient-data based meta-analysis.BMC medicine · 2023Pooled it
- Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Trial
- Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.Nature medicine · 2025Trial
- Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.Journal for immunotherapy of cancer · 2024Trial
- A Real-World Assessment of Stage I Lung Cancer Through Electronic Nose Technology.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2024Trial
- Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial.Nature communications · 2023Trial
- Tislelizumab plus chemotherapy for patients withJournal for immunotherapy of cancer · 2023Trial
- Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Second-Line Therapy Following Osimertinib in Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer at an Academic Medical Center.Cancer reports (Hoboken, N.J.) · 2026Article
- Clinical Value of a 51-Neuroendocrine Tumor-Specific Gene Signature (NETest 2.0) for Management of Pancreatic and Small Bowel Neuroendocrine Tumors: A Prospective Study in a Consecutive Cohort of 82 Patients Considered for Surgery.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2026Article
- Molecular Residual Disease in Non-Small Cell Lung Cancer: Technology or Patient Outcomes?Journal of personalized medicine · 2026Review
- ITHindex: An integrated web-based platform for intratumor heterogeneity evaluation.PLOS digital health · 2026Article
- Interpretable deep learning model of circulating genomics for quantitative survival prediction in advanced non-small cell lung cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Circulating Tumor DNA Analysis in Adrenocortical Carcinoma: A Retrospective Cohort Study.Endocrine pathology · 2026Article
- Article
- Clinicopathological characteristics of patients with inoperable non-small cell lung cancer harboring circulating NRF2 pathway mutations.The Journal of pathology · 2026Article
55 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
72 authors at 3 institutions in 3 countries.
Justin JeeMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9783-0139
Emily S LebowMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Randy YehMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2945-5546
Jeeban P DasMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Azadeh NamakydoustMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul K PaikMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Jamie E ChaftMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5838-9982
Gowtham JayakumaranMemorial Sloan Kettering Cancer Center, New York, NY, USA.
A Rose BrannonMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4610-0149
Ryma BenayedMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3754-0321
Ahmet ZehirMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5406-4104
Mark DonoghueMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Nikolaus SchultzMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0131-4904
Debyani ChakravartyMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-8629-5732
Ritika KundraMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6723-2859
Ramyasree MadupuriMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Yonina R Murciano-GoroffMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Hai-Yan TuMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Chong-Rui XuMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3474-2809
Andrés MartinezMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Clare WilhelmMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Jesse GalleMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Bobby DalyMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Helena A YuMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-0377-9510
Michael OffinMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7959-3018
Matthew D HellmannMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Piro LitoMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2196-3503
Kathryn C ArbourMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5951-8427
Marjorie G ZaudererMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-6109-5790
Mark G KrisMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth K NgMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Juliana EngMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Isabel PreeshagulMemorial Sloan Kettering Cancer Center, New York, NY, USA.
W Victoria LaiMemorial Sloan Kettering Cancer Center, New York, NY, USA.
John J FioreMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Afsheen IqbalMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Daniela MolenaMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-1655-4473
Gaetano RoccoMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Bernard J ParkMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Lee P LimResolution Bioscience, Agilent Technologies, Kirkland, WA, USA.
Mark LiResolution Bioscience, Agilent Technologies, Kirkland, WA, USA.
Candace Tong-LiGenesisCare, University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0003-2733-5225
Madhawa De SilvaGenesisCare, University of Sydney, Sydney, Australia.
David L ChanGenesisCare, University of Sydney, Sydney, Australia.
Connie I DiakosGenesisCare, University of Sydney, Sydney, Australia.
Malinda ItchinsGenesisCare, University of Sydney, Sydney, Australia.
Stephen ClarkeGenesisCare, University of Sydney, Sydney, Australia.ORCID http://orcid.org/0000-0001-5817-1222
Nick PavlakisGenesisCare, University of Sydney, Sydney, Australia.
Adrian LeeGenesisCare, University of Sydney, Sydney, Australia.
Natasha RekhtmanMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Jason ChangMemorial Sloan Kettering Cancer Center, New York, NY, USA.
William D TravisMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Gregory J RielyMemorial Sloan Kettering Cancer Center, New York, NY, USA.
David B SolitMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-6614-802X
Mithat GonenMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Valerie W RuschMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Andreas RimnerMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-1214-3856
Daniel GomezMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexander DrilonMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6806-9061
Howard I ScherMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Sohrab P ShahMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-6402-523X
Michael F BergerMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-3882-5000
Maria E ArcilaMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Marc LadanyiMemorial Sloan Kettering Cancer Center, New York, NY, USA.
Ross L LevineMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7884-1905
Ronglai ShenMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-9694-584X
Pedram RazaviMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-4236-0576
Jorge S Reis-FilhoMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0003-2969-3173
David R JonesMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-3318-0146
Charles M RudinMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5204-3465
James M IsbellMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-7305-876X
Bob T LiMemorial Sloan Kettering Cancer Center, New York, NY, USA. lib1@mskcc.org.ORCID http://orcid.org/0000-0001-6661-8733
Memorial Sloan Kettering Cancer Center · USThe University of Sydney · AUAgilent Technologies (United States) · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MDisparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2MClinical and Translational Science CenterUL1TR000457 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI IMPERATO-MCGINLEY, JULIANNE L · 2012 to 2016
$46.0MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2007 to 2026
$31.2MTargeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Sarat Chandarlapaty, Simon N. Powell · 2020 to 2026
$16.3MInvestigational Cancer Therapeutics Training Program (ICTTP)T32CA009207 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Omar Abdel-Wahab, Alexander Drilon · 1985 to 2026
$13.7MDissecting KRAS oncoprotein signaling with small molecule inhibitorsR01CA230745 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2018 to 2026
$3.8MStudies on the effects of a novel intermittent therapy on intratumoral clonal architecture and resistanceR01CA230267 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LITO, PIRO · 2019 to 2023
$2.0MMechanisms of adaptation and resistance to emerging therapies for lung cancerR01CA279264 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Piro Lito · 2023 to 2026
$2.0MNCATS NIH HHS UL1 TR000457NCATS NIH HHS UL1 TR001873NCATS NIH HHS UL1 TR002384NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA247749NCI NIH HHS R01 CA230267NCI NIH HHS R01 CA230745NCI NIH HHS R01 CA279264NCI NIH HHS T32 CA009207
Abstract
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively followed an international cohort of 1,127 patients with non-small-cell lung cancer and ctDNA-guided therapy. ctDNA detection was associated with shorter survival (hazard ratio (HR), 2.05; 95% confidence interval (CI), 1.74-2.42; P < 0.001) independently of clinicopathologic features and metabolic tumor volume. Among the 722 (64%) patients with detectable ctDNA, 255 (23%) matched to targeted therapy by ctDNA sequencing had longer survival than those not treated with targeted therapy (HR, 0.63; 95% CI, 0.52-0.76; P < 0.001). Genomic alterations in ctDNA not detected by time-matched tissue sequencing were found in 25% of the patients. These ctDNA-only alterations disproportionately featured subclonal drivers of resistance, including RICTOR and PIK3CA alterations, and were associated with short survival. Minimally invasive ctDNA profiling can identify heterogeneous drivers not captured in tissue sequencing and expand community access to life-prolonging therapy.
Indexed as
Carcinoma, Non-Small-Cell LungCirculating Tumor DNALung NeoplasmsBiomarkers, TumorHigh-Throughput Nucleotide SequencingHumansMutationBiomarkers, TumorCirculating Tumor DNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.